QR Pharma Completes $2.4 Million Seed Financing with Round-Closing Investments from BioAdvance and Angels to Advance Clinical Development of two Alzheimer’s Disease Compounds

Published: Jun 02, 2010

RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, announced today a $500,000 investment from BioAdvance and additional funding from Angel Investors. These investments closed a total of $2.4 million seed round, which QR opened a year ago, including Ben Franklin Technology Partner’s $500,000 investment as well as other private investor funds.

Back to news